德琪醫藥-B(06996.HK)提交ATG-018抑制劑澳洲I期臨牀試驗申請
德琪醫藥-B(06996.HK)宣佈,已向澳大利亞人類研究倫理委員會(HREC)遞交ATG-018用於治療晚期實體瘤及血液腫瘤患者的I期(ATRIUM研究)臨牀試驗申請。
該研究的主要目的爲評估ATG-018單藥治療的安全性、耐受性,以確定II期推薦劑量並在可能的情況下評估該療法的初步有效性;次要目的爲確定ATG-018的藥理特性。
ATG-018是由德琪醫藥研發團隊自主開發,用於共濟失調性毛細血管擴張和Rad3-相關(ATR)激(酉每)的口服、強效、選擇性小分子抑制劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.